123 related articles for article (PubMed ID: 35235990)
1. Survival Analysis of Surgically Resected ypN2 Lung Cancer after Neoadjuvant Therapy.
İşgörücü Ö; Citak N
Thorac Cardiovasc Surg; 2023 Apr; 71(3):206-213. PubMed ID: 35235990
[TBL] [Abstract][Full Text] [Related]
2. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
3. [Lung cancer: is surgery an option for persisting N2 after induction therapy?].
Haager B; Osei-Agyemang T; Passlick B; Wiesemann S
Zentralbl Chir; 2015 Feb; 140(1):99-103. PubMed ID: 25076164
[TBL] [Abstract][Full Text] [Related]
4. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.
Ripley RT; Suzuki K; Tan KS; Adusumilli PS; Huang J; Park BJ; Downey RJ; Rizk NP; Rusch VW; Bains M; Jones DR
J Thorac Cardiovasc Surg; 2016 Apr; 151(4):969-77, 979.e1-3. PubMed ID: 26614420
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
Kim HK; Cho JH; Choi YS; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Kim K; Kim J
Lung Cancer; 2016 Jun; 96():56-62. PubMed ID: 27133751
[TBL] [Abstract][Full Text] [Related]
6. Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment.
Stamatis G; Müller S; Weinreich G; Schwarz B; Eberhardt W; Pöttgen C; Aigner C
Eur J Cardiothorac Surg; 2022 Jan; 61(2):269-276. PubMed ID: 34368849
[TBL] [Abstract][Full Text] [Related]
7. Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).
Ma Q; Liu D; Guo Y; Shi B; Song Z; Tian Y
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):342-8. PubMed ID: 20677562
[TBL] [Abstract][Full Text] [Related]
8. Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk?
Steger V; Walker T; Mustafi M; Lehrach K; Kyriss T; Veit S; Friedel G; Walles T
Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):948-53. PubMed ID: 22997251
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant radiation therapy improves survival in stage IIIA (N2) non-small cell lung cancer with persistent N2 disease after neoadjuvant chemotherapy.
Komiya T; Takamori S; Wilding G
Radiother Oncol; 2022 Nov; 176():234-238. PubMed ID: 36192229
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease.
Iwasaki A; Shirakusa T; Miyoshi T; Hamada T; Enatsu S; Maekawa S; Hiratsuka M
Thorac Cardiovasc Surg; 2006 Feb; 54(1):42-6. PubMed ID: 16485188
[TBL] [Abstract][Full Text] [Related]
11. Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.
Brandt WS; Yan W; Leeman JE; Tan KS; Park BJ; Adusumilli PS; Bott MJ; Molena D; Isbell J; Chaft J; Rimner A; Jones DR
Ann Thorac Surg; 2018 Sep; 106(3):848-855. PubMed ID: 29807005
[TBL] [Abstract][Full Text] [Related]
12. Persistent N2 After Induction Is Not a Contraindication to Surgery for Lung Cancer.
Andrews WG; Louie BE; Castiglioni M; Dhamija A; Farivar AS; Chansky J; White PT; Aye RW; Vallières E; Bograd AJ
Ann Thorac Surg; 2022 Aug; 114(2):394-400. PubMed ID: 34890568
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of multi-level N2-positive non-small cell lung cancer according to lymph node staging using endobronchial ultrasound-transbronchial biopsy.
Yoon HY; Lee JC; Kim SW; Kim HR; Kim YH; Choi SH; Kim SS; Song SY; Choi EK; Jang SJ; Choi CM
Thorac Cancer; 2018 Jun; 9(6):684-692. PubMed ID: 29607613
[TBL] [Abstract][Full Text] [Related]
14. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
[TBL] [Abstract][Full Text] [Related]
15. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario.
Kumar S; Saikia J; Kumar V; Malik PS; Madan K; Jain D; Bharati S
Curr Probl Cancer; 2020 Jun; 44(3):100563. PubMed ID: 32265058
[TBL] [Abstract][Full Text] [Related]
17. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.
Veeramachaneni NK; Feins RH; Stephenson BJ; Edwards LJ; Fernandez FG
Ann Thorac Surg; 2012 Sep; 94(3):922-6; discussion 926-8. PubMed ID: 22742842
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
[TBL] [Abstract][Full Text] [Related]
20. The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe.
Sakao Y; Okumura S; Mingyon M; Uehara H; Ishikawa Y; Nakagawa K
J Thorac Oncol; 2011 Mar; 6(3):494-9. PubMed ID: 21266920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
